tbuckley/cabot-search huggingface dataset:
HSP90 inhibitor geldanamycin reverts IL-13– and IL-17–induced airway goblet cell metaplasia
Authors: Alejandro A. Pezzulo, Rosarie A. Tudas, Carley G. Stewart, Luis G. Vargas Buonfiglio, Brian D. Lindsay, Peter J. Taft, Nicholas D. Gansemer, Joseph Zabner
Journal: Journal of Clinical Investigation (2019)

Goblet cell metaplasia, a disabling hallmark of chronic lung disease, lacks curative treatments at present. To identify novel therapeutic targets for goblet cell metaplasia, we studied the transcriptional response profile of IL-13-exposed primary human airway epithelia in vitro and asthmatic airway epithelia in vivo. A perturbation-response profile connectivity approach identified geldanamycin, an inhibitor of heat shock protein 90 (HSP90) as a candidate therapeutic target. Our experiments confirmed that geldanamycin and other HSP90 inhibitors prevented IL-13-induced goblet cell metaplasia in vitro and in vivo. Geldanamycin also reverted established goblet cell metaplasia. Geldanamycin did not induce goblet cell death, nor did it solely block mucin synthesis or IL-13 receptor-proximal signaling. Geldanamycin affected the transcriptome of airway cells when exposed to IL-13, but not when exposed to vehicle. We hypothesized that the mechanism of action probably involves TGF-β, ERBB, or EHF, which would predict that geldanamycin would also revert IL-17-induced goblet cell metaplasia, a prediction confirmed by our experiments. Our findings suggest that persistent airway goblet cell metaplasia requires HSP90 activity and that HSP90 inhibitors will revert goblet cell metaplasia, despite active upstream inflammatory signaling. Moreover, HSP90 inhibitors may be a therapeutic option for airway diseases with goblet cell metaplasia of unknown mechanism.
Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS
Authors: Andrea Kuendgen, Meritxell Nomdedeu, Heinz Tuechler, Guillermo Garcia-Manero, Rami S. Komrokji, Mikkael A. Sekeres, Matteo Giovanni Della Porta, Alan F. List, Mario Cazzola, Amy E. DeZern, Gail J. Roboz, David P. Steensma, Arjan A. Van de Loosdrecht, Hartmut Döhner, Xavier Calvo, Sabine Blum, Arturo Pereira, Peter Valent, Dolors Costa, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, Carme Pedro, Michael Lübbert, Itziar Oiartzabal, Javier Grau, Maria Díez-Campelo, María Teresa Cedena, Sigrid Machherndl-Spandl, Maria López-Pavía, Claudia D. Baldus, Montserra Martinez-de-Sola, Reinhard Stauder, Brayan Merchan, Christina Ganster, Thomas Schroeder, Barbara Hildebrandt, Jordi Esteve, Benet Nomdedeu, Francesc Cobo, Francesc Sole, Rainer Haas, Ulrich Germing, Peter L Greenberg, Detlef Haase, Guillermo Sanz
Journal: Blood (2018)
AB0054 Pde4 inhibitor attenuation of il-23 secretion from mononuclear cells
Authors: C. Bridgewood, R. Cuthbert, M. Wittmann, D. McGonagle
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> IL-23 is a cytokine heavily implicated in the immunopathology of both psoriasis and psoriatic arthritis. Emerging evidence suggest IL-36λ, a novel inflammatory cytokine which has been heavily implicated in psoriatic immunopathology, is able to stimulate the release of IL-23.<sup>1–3</sup> PDE4 inhibitors, which elevate cyclic AMP (cAMP) are known to exert anti-inflammatory effects by regulating transcription factors such as NF-κB. The PDE4 inhibitor, Apremilast has proved successful in treating both psoriasis and psoriatic arthritis with patients showing a decrease in inflammatory cytokine levels, including IL-23.<sup>4</sup> However, the ability and mechanism of PDE4 inhibitors to lower IL-23 secretion from immune cells induced by disease relevant stimuli is presently unknown. Additionally, any potential relationship between IL-36λ driven inflammation and potential PDE4 inhibition is yet to be determined. <h3>Methods</h3> Blood mononuclear cells from healthy patients, (n=5) were pre-treated with either the PDE4 inhibitor Rolipram or other compounds known to elevate cAMP levels, such as histamine and 8-bromo-cAMP. Cells were subsequently treated with either bacterial or fungal toll like receptor adjuvants (LPS and Mannan) or the novel psoriatic cytokine IL-36λ. IL-23 was subsequently measured in culture supernatants by ELISA and by intracellular IL-23p19 flow cytometry. <h3>Results</h3> LPS, Mannan and IL-36λ all induced IL-23 secretion which could be attenuated in a dose dependent manner by the PDE4 inhibitor, Rolipram. Other compounds also known to increase cAMP levels, histamine and 8-bromo-cAMP similarly were able to reduce IL-23 secretion from all stimuli. <h3>Conclusions</h3> This data suggests a direct link between PDE4 inhibition and reduced IL-23 secretion in circulating immune cells. Additionally, it provides insight into of how IL36/IL-23/IL-17 driven inflammation may be reduced by PDE4 inhibitors in psoriasis and psoriatic arthritis. <h3>References</h3> [1] Gabay C, Towne JE. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leukoc Biol2015;97(4):645–652. [2] Chi HH, et al. IL-36 Signaling Facilitates Activation of the NLRP3 Inflammasome and IL-23/IL-17 Axis in Renal Inflammation and Fibrosis. J Am Soc Nephrol2017;28(7):2022–2037. [3] Bridgewood C, et al. IL-36γ is a strong inducer of IL-23 production and angiogenesis in psoriasis. Frontiers in Immunology2018;9:200. [4] Keating GM. Apremilast: A Review in Psoriasis and Psoriatic Arthritis. Drugs2017;77(4):459–472. <h3>Disclosure of Interest</h3> None declared
OP0355 Pulmonary thromboendarterectomy is a curative resolution for chronic thromboembolic pulmonary hypertension associated with primary antiphospholipid syndrome: a retrospective cohort study
Authors: C. Li, J.L. Zhao, Y. Zhao, S. Liu, Q. Wang, M.T. Li
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and life-threatening condition with a poor prognosis in antiphospholipid syndrome (APS) patients. A specialised and multidisciplinary evaluation are needed for APS associated CTEPH. As a curative option for CTEPH, pulmonary thromboendarterectomy (PTE) requires careful risk and benefit assessment in APS patients. <h3>Objectives</h3> This retrospective cohort study aimed to investigate the clinical manifestations and prognosis of CTEPH in APS patients with or without PTE. <h3>Methods</h3> Consecutive patients with APS associated CTEPH diagnosed between January 2012 to September 2017 at Peking Union Medical College Hospital were retrospectively evaluated. Patients were divided into two groups by whether underwent PTE or not. Demographics, clinical manifestations, antiphospholipid antibodies profiles, target medications, treatment were collected as possible influencing factors. Chi-square test was used to analyse the short-term prognosis while Kaplan Meier curve and log rank test were used to analyse long-term prognosis (outcome events: deterioration of cardiac function or death). <h3>Results</h3> A total of the 20 APS associated CTEPH patients were enrolled, 8 underwent PTE and 12 without PTE. Common CTEPH developed by these patients included chest pain, dyspnea on exertion, cough and hemoptysis. Chi-square test (p=0.01) and Kaplan Meier curves (Log rank test, p=0.04) showed that there was statistically significant difference in both short-term and long-term prognosis among patients with PTE and without PTE. On the other hand, Cox regression analysis showed diagnosis (PAPS or SLE-APS), aPL (antiphospholipid antibody) profiles, thrombocytopenia, other Thrombotic Events, target therapies, baseline WHO FC have no effects on the prognosis of CTEPH in patients with APS. <h3>Conclusions</h3> After a full specialised and multidisciplinary risk-benefit evaluation to limit the risk of thrombosis or bleeding and to manage possible thrombocytopenia, for those CTEPH developed in APS patients, PTE is a curative resolution. <h3>Disclosure of Interest</h3> None declared
RIGHT ATRIAL FUNCTION IN HEART FAILURE WITH PRESERVED AND REDUCED EJECTION FRACTION
Authors: Julio A. Chirinos, Vaibhav Satija, Swetha Gaddam, Rachana Miller, Khuzaima Javaid, Danny Kuriakose, Ilaina Edelstein, Yueya Ge, Pritika Manaktala, Scott Akers
Journal: Journal of the American College of Cardiology (2018)
FOXM1 and the NPM-ALK/STAT3 Axis Form a Novel Positive Feedback Loop in Promoting the Oncogenesis of ALK-Positive Anaplastic Large Cell Lymphoma
Authors: Peng Wang, Moinul Haque, Jing Li, Yung-Hsing Huang, Meaad Almowaled, Carter Bargar, Adam Karpf, Will Chen, Suzanne Turner, Raymond Lai
Journal: Blood (2018)
AB1219 Contribution of mri to cervical involvement in rheumatoid arthritis: prospective study of 30 cases
Authors: S. rekik, K. Zouaoui, S. boussaid, H. sehli, E. cheour, M. elleuch
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Cervical spine involvement is common during RA and is characterised by its potential severity. <h3>Objectives</h3> To determine the prevalence of cervical involvement in RA, to clarify the contribution of MRI to diagnosis and to identify predictive factors for cervical rheumatoid involvement. <h3>Methods</h3> Our study included 30 RA patients with a duration of more than 2 years. <h3>Results</h3> 16 patients (53%) were assessed on the two imaging methods (standard radiographs in 37% and MRI in 53%), of which 2 cases (7%) were asymptomatic. This cervical involvement was dominated by the C1-C2 pannus objectivated in 50% of cases and AAS. Of the AAS, aAAS was the most frequent with a prevalence of 23%, followed by the pAAS found in 10% of the cases, the vAAS present in 7% of the cases then the lAAS and the rAAS objectivated in 3% each. The ASS was found in 3 cases(10%), odontoid erosion in 11 cases (37%), C1-C2 arthritis in 5 cases (16%) and inflammatory spondylodiscitis in 6 cases (20%). MRI resulted in a better study of the C1-C2 pannus and odontoid erosions as well as the evaluation of the impact of rheumatoid lesions on the neural axis: a medullary imprint was noted in 4 cases (13%). Several factors were associated with cervical rheumatoid involvement: the presence of cervicobrachial neuralgia or bulbomedullary signs, duration of PR ≥5 years, HAQ score ≥1.1 and positive RF. The search for factors associated with AAS has revealed the duration of the disease, DAS 28≥3.2 and the presence of a biological inflammatory syndrome. <h3>Conclusions</h3> Cervical involvement accompanies the active and destructive forms of RA. It can be asymptomatic, it is the interest to seek it in a systematic way in RA. The standard radiography with dynamic views is to be realised first-line. The MRI must be indicated in order to make an early diagnosis, to carry out an accurate lesional assessment and to guide the therapeutic decision. <h3>Disclosure of Interest</h3> None declared
THU0438 Comparative study of infliximab versus adalimumab in refractory uveitis associated to cystoid macular oedemadue to behÇet’s disease. mulcitenter study of 40 cases
Authors: B. Atienza-Mateo, V. Calvo-Río, J.L. Martín-Varillas, R. Demetrio-Pablo, E. Beltrán, M. Gandía, M. Mesquida, A. Adan, M.V. Hernández, D. Díaz, E. Valls, L. Martinez, M. Cordero, M. Díaz, J.M. Herreras, O. Maiz, A. Blanco, I. Torre, M. García, F. Francisco, S. Insua, R. Almodóvar, O. Ruiz, F. Jiménez, J. Manero, J.M. Nolla, M. Hernandez, M.A. González-Gay, R. Blanco
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as first biologic drug in refractory uveitis with cystoid macular oedema (CME) associated to BD. <h3>Methods</h3> Multicenter study of 40 patients with BD-associated uveitis with CME refractory or intolerant to standard treatment (corticosteroids and at least one conventional immunosuppressive agent). CME was considered if macular thickness was greater than 300 µm. Comparative outcome measures were macular thickness, improvement of visual acuity (VA), activity of anterior chamber inflammation and vitritis. Results were expressed as mean ±SD for variables with a normal distribution, or as median [25th-75th interquartile range- IQR] when not normally distributed. The comparison of continuous variables among time-periods was performed with the Wilcoxon signed rank test. <h3>Results</h3> We selected patients with CME from a cohort of 177 patients with refractory BD-related uveitis (n=40). IFX was used in 15 cases and ADA in 25. No significant differences at baseline were observed between IFX vs ADA groups in sex (♂/♀ 8/7 vs 13/12, p=0.93), mean age (38±9 vs 41±10 years, p=0.53), HLA-B51 + (10 vs 19, p=0.87), uveitis pattern (panuveitis 67% vs 80%, posterior uveitis 33% vs 20%, p=0.34), previous conventional treatment (intravenous pulses of methylprednisolone 60% vs 52%, p=0.62, oral corticosteroids 93% vs 72%, p=0.1, methotrexate 53% vs 52%, p=0.93, cyclosporin A 73% vs 88%, p=0.23, azathioprine 53% vs 56%, p=0.86, other drugs 47% vs 68%, p=0.18), and combined treatment (67% vs 64%, p=0.86). After 1 year of therapy<b>,</b> ocular remission was achieved in 60% of cases with IFX and in 76% of cases with ADA (p=0.28). Regarding CME, 65% of patients with IFX reached a macular thickness &lt;250 µm vs 87% of patients with ADA, with no statistically significant differences (p=0.07). Evolution of ocular parameters is shown in the table 1. Only 2 adverse effects were observed, both in ADA group (local rash and bacteremia). <h3>Conclusions</h3> IFX and ADA show a similar efficacy in the treatment of CME in BD-related refractory uveitis. <h3>Reference</h3> [1] Calvo-Río V, Blanco R, Beltran E, Sanchez-Burson J, Mesquida M, Adan A, et al. Anti-TNF- therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford)2014;53(12):2223–31. <h3>Disclosure of Interest</h3> None declared
Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank
Authors: Luke C Pilling, Jone Tamosauskaite, Garan Jones, Andrew R Wood, Lindsay Jones, Chai-Ling Kuo, George A Kuchel, Luigi Ferrucci, David Melzer
Journal: BMJ (2019)

Abstract Objective To compare prevalent and incident morbidity and mortality between those with the HFE p.C282Y genetic variant (responsible for most hereditary haemochromatosis type 1) and those with no p.C282Y mutations, in a large UK community sample of European descent. Design Cohort study. Setting 22 centres across England, Scotland, and Wales in UK Biobank (2006-10). Participants 451 243 volunteers of European descent aged 40 to 70 years, with a mean follow-up of seven years (maximum 9.4 years) through hospital inpatient diagnoses and death certification. Main outcome measure Odds ratios and Cox hazard ratios of disease rates between participants with and without the haemochromatosis mutations, adjusted for age, genotyping array type, and genetic principal components. The sexes were analysed separately as morbidity due to iron excess occurs later in women. Results Of 2890 participants homozygous for p.C282Y (0.6%, or 1 in 156), haemochromatosis was diagnosed in 21.7% (95% confidence interval 19.5% to 24.1%, 281/1294) of men and 9.8% (8.4% to 11.2%, 156/1596) of women by end of follow-up. p.C282Y homozygous men aged 40 to 70 had a higher prevalence of diagnosed haemochromatosis (odds ratio 411.1, 95% confidence interval 299.0 to 565.3, P&lt;0.001), liver disease (4.30, 2.97 to 6.18, P&lt;0.001), rheumatoid arthritis (2.23, 1.51 to 3.31, P&lt;0.001), osteoarthritis (2.01, 1.71 to 2.36, P&lt;0.001), and diabetes mellitus (1.53, 1.16 to 1.98, P=0.002), versus no p.C282Y mutations (n=175 539). During the seven year follow-up, 15.7% of homozygous men developed at least one incident associated condition versus 5.0% (P&lt;0.001) with no p.C282Y mutations (women 10.1% v 3.4%, P&lt;0.001). Haemochromatosis diagnoses were more common in p.C282Y/p.H63D heterozygotes, but excess morbidity was modest. Conclusions In a large community sample, HFE p.C282Y homozygosity was associated with substantial prevalent and incident clinically diagnosed morbidity in both men and women. As p.C282Y associated iron overload is preventable and treatable if intervention starts early, these findings justify re-examination of options for expanded early case ascertainment and screening.
THU0439 Tocilizumab in giant cell arteritis. national multicenter study of 134 patients of clinical practice
Authors: D. Prieto-Peña, J. Loricera, J. Martín-V, M. Calderón-G, V. Aldasoro, M. Varela-G, R. Ibánez-B, I. Villa, E. Aurrecoechea, S. Castañeda, A. Humbría, E. Díez, C. Moriano, S. Romero-Y, J. Narváez, C. Gómez-A, A. Mera, E. Pérez-P, R. Dos Santos, C. Barbazán, R. Melero, E. Becerra-F, Á. García, M. Revenga, C. Larena, E. Miguel, N. Álvarez-R, C. Galisteo, F. Sivera, A. Olivé-M, A. Prior, M. Álvarez, L. Marena-R, C. Fernández-L, F. Navarro, E. Raya, N. Ortego, E. Galíndez-A, B. Arca, S. Fernández, R. Solans-L, A. Conesa, C. Hidalgo, C. Vázquez, J. Román-I, F. Ortiz-S, P. Lluch, S. Manrique-A, P. Vela, C. Torres-M, J. Nieto, C. Ordas-C, E. Salgado-P, C. Gómez, J. Toyos, I. Hernández, F. Maceiras-P, N. Fernández-L, A. García, N. Palmou-F, V. Calvo-R, C. González-V, L. Domínguez-C, A. Corrales, J. Hernández, M. González-Gay, R. Blanco
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Giant cell arteritis (GCA) can be refractory to corticosteroids<sup>1–3</sup>. Tocilizumab (TCZ) demonstrated to be effective in two short-term clinical trials. <h3>Objectives</h3> To assess efficacy of TCZ in refractory GCA or with side effects to corticosteroids in clinical practice. <h3>Methods</h3> Multicenter study on 134 patients with GCA in treatment with TCZ due to lack of efficacy and/or unacceptable adverse events of previous therapy. <h3>Results</h3> 134 patients (101 w/33 m); mean age of 73.0±8.8 years. Main clinical features at TCZ onset were: PMR (n=73), constitutional syndrome (n=31), headache (n=70), visual (n=28) and jaw (n=14) affection. Besides steroids, 98 patients also received immunosuppressive agents. table 1 shows evolution during follow-up period. After a median follow-up of 12 [3.7–24] months, it was observed a decrease in:<b>a)</b>CRP from 1.7 [0.4–3.2] to 0.1 [0.0–0.3] mg/dL <b>b)</b>ESR from 33 [14.5–61] to 4<sup>2–9</sup> mm/1st hour and <b>c)</b> Prednisone dose from 15<sup>10–30</sup> to 5 [0–7.5] mg/day. Outcome of patients was:<b>a)</b>discontinuation of TCZ (n=15) due to sustained remission, <b>b)</b>dose reduction due to improvement (n=17) or side effects (n=11), <b>c)</b>withdrawal of TCZ because of side effects (n=12) and <b>d)</b>same dose that at onset (n=73). TCZ had to be discontinued due to: infections, haematological and cardiovascular alterations, neoplasms and heptic toxicity among the most frequent. <h3>Table 1</h3> <h3>Conclusions</h3> TCZ leads to a rapid and maintained improvement in patients with refractory GCA and/or with unacceptable side effects related to corticosteroids. However, the risk of neutropenia and infection should be kept in mind. <h3>References</h3> [1] Loricera J, et al. Semin Arthritis Rheum2015;44:717–723. [2] Loricera J, et al. Clin Exp Rheumatol2014;32(3Suppl82):S79–89. [3] Loricera J, et al. Clin Exp Rheumatol2016; 34 (3 Suppl 97):S44–53. <h3>Disclosure of Interest</h3> None declared
Abstract 16838: Adaptive Behavior and Quality of Life at 6 years for Children With Hypoplastic Left Heart Syndrome and Related Abnormalities: Findings From the Pediatric Heart Network Single Ventricle Extension Study
Authors: Caren S Goldberg, Chenwei Hu, Cheryl Brosig, J. William Gaynor, William T Mahle, Thomas Miller, Kathleen A Mussatto, Renee Sananes, Karen C Uzark, Felicia Trachtenbburg, Christian Pizarro, Victoria L Pemberton, Alan B Lewis, Jennifer S Li, Jeffrey Jacobs, James Cnota, Andrew Atz, Wyman Lai, David C Bellinger, Jane W Newburger
Journal: Circulation (2017)

Introduction: Among congenital heart defects, hypoplastic left heart syndrome (HLHS) portends the greatest risk of neurodevelopmental impairment. We sought to determine risk factors for worse adapt...
Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques
Authors: Karin Dijkman, Claudia C. Sombroek, Richard A. W. Vervenne, Sam O. Hofman, Charelle Boot, Edmond J. Remarque, Clemens H. M. Kocken, Tom H. M. Ottenhoff, Ivanela Kondova, Mohammed A. Khayum, Krista G. Haanstra, Michel P. M. Vierboom, Frank A. W. Verreck
Journal: Nature Medicine (2019)
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease
Authors: Oliver Preische, Stephanie A Schultz, Anja Apel, Jens Kuhle, Stephan A Kaeser, Christian Barro, Susanne Gräber, Elke Kuder-Buletta, Christian LaFougere, Christoph Laske, Jonathan Vöglein, Johannes Levin, Colin L Masters, Ralph Martins, Peter R Schofield, Martin N Rossor, Neill R Graff-Radford, Stephen Salloway, Bernardino Ghetti, John M Ringman, James M Noble, Jasmeer Chhatwal, Alison M Goate, Tammie L S Benzinger, John C Morris, Randall J Bateman, Guoqiao Wang, Anne M Fagan, Eric M McDade, Brian A Gordon, Mathias Jucker
Journal: Nature Medicine (2019)
Impact of Pre-Intervention Transaortic Flow Rate Versus Stroke Volume Index on Mortality Across the Hemodynamic Spectrum of Severe Aortic Stenosis
Authors: Anastasia Vamvakidou, Wenying Jin, Oleksandr Danylenko, Jiwan Pradhan, Wei Li, Cathy West, Rajdeep Khattar, Roxy Senior
Journal: JACC. Cardiovascular imaging (2019)
OP0236 Risk of cardiovascular disease and venous thromboembolism among patients with incident anca-associated vasculitis: a 20 year population-based cohort study
Authors: A Berti, E. Matteson, C.S. Crowson, U. Specks, D. Cornec
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Although modern treatments have greatly improved survival in ANCA-associated vasculitis (AAV), many patients suffer cardiovascular and thrombotic complications during long-term follow up. <h3>Objectives</h3> We aimed to assess the cardiovascular disease (CVD) and venous thromboembolism (VTE) risks among patients with newly diagnosed AAV. <h3>Methods</h3> A population-based incident AAV cohort of 58 patients diagnosed between 1996 and 2015 in Olmsted County (Minnesota, USA) was identified by medical record review. For each patient, 3 age- and sex-matched non-AAV comparators were randomly selected from the same population and assigned an index date corresponding to the AAV incidence date. Medical records of cases and comparators were reviewed for CVD events, which included cardiac events (coronary artery disease, heart failure and atrial fibrillation), cerebrovascular accidents (CVA), peripheral vascular disease (PVD) and VTE, which included deep vein thrombosis (DVT) and pulmonary embolism (PE). <h3>Results</h3> Baseline total cholesterol, high-density lipoprotein and current smoking rate were lower in AAV than comparators (p<i>=0.03</i>, p<i>=0.01 and</i> p<i>=0.04</i>, respectively), while other CVD risk factors and Framingham risk score were not significantly different between the 2 groups. CVD events developed in 13 patients and 17 comparators, corresponding to a&gt;3 fold increased risk (hazard ratio [HR] 3.15; 95% confidence interval [CI]:1.51–6.57) (figure 1). By subtypes, risks were increased for cardiac events (HR 2.96, 95% CI: 1.42 to 6.15) and CVA (HR 8.16, 95% CI: 2.45 to 27.15), but not for PVD. The HR for VTE was 3.26 (95% CI: 0.84 to 12.60), significantly increased for DVT (HR 6.25, 95% CI: 1.16 to 33.60), but not for PE (HR 1.33, 95% CI: 0.23 to 7.54). <h3>Conclusions</h3> Despite a similar prevalence of CVD risk factors at baseline, the risk of CVD is &gt;3 fold higher and for CVA 8-fold higher in patients with incident AAV than matched comparator subjects. <h3>References</h3> [1] Avina-Zubieta JA, Mai A, et al. Risk of myocardial infarction and stroke in patients with granulomatosis with polyangiitis (Wegener's): A population-based study.<i>Arthritis Rheumatol</i>2016;68(11):2752–9. [2] Morgan MD, et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: A matched-pair cohort study. Arthritis Rheum2009;60(11):3493–500. <h3>Disclosure of Interest</h3> None declared